8 August 2018 - NICE has published evidence-based recommendations on the use of ixekizumab (Taltz) on the NHS for the treatment of adults with active psoriatic arthritis.

Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:

• it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis or
  
• the person has had a tumour necrosis factor (TNF)-alfa inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks or
  
• TNF-alfa inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
  

Ixekizumab is only recommended if the company provides it according to the commercial arrangement.

Read NICE Final Appraisal Determination for ixekizumab (Taltz)